Evidence map›Paper›PMID 35743420›Full record

ArticleJournal of clinical medicine2022

Thyroid-Stimulating Hormone Predicts Total Cholesterol and Low-Density Lipoprotein Cholesterol Reduction during the Acute Phase of COVID-19.

Massimo Raffaele Mannarino, Vanessa Bianconi, Elena Cosentini, Filippo Figorilli, Cecilia Colangelo, Francesco Giglioni, Rita Lombardini, Rita Paltriccia, Matteo Pirro

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Distinct Features of Vascular Diseases in COVID-19.Journal of inflammation research · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Massimo Raffaele MannarinoUnit of Internal Medicine, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy.ORCID 0000-0003-4694-5504
Vanessa BianconiUnit of Internal Medicine, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy.
Elena CosentiniUnit of Internal Medicine, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy.
Filippo FigorilliUnit of Internal Medicine, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy.
Cecilia ColangeloUnit of Internal Medicine, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy.
Francesco GiglioniUnit of Internal Medicine, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy.
Rita LombardiniUnit of Internal Medicine, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy.ORCID 0000-0001-7682-9817
Rita PaltricciaUnit of Internal Medicine, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy.
Matteo PirroUnit of Internal Medicine, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy.
University of Perugia · IT

Funding

Fondazione Cassa di Risparmio di Perugia 20422(2021.0343)
6 · The paper itself

Abstract

A complex dysregulation of lipid metabolism occurs in COVID-19, leading to reduced total cholesterol (TC), LDL-cholesterol (LDL-C), and HDL-cholesterol (HDL-C) levels, along with a derangement of thyroid function, leading to reduced thyroid-stimulating hormone (TSH) levels. This study aimed to explore the association between TSH levels during COVID-19 and the variation (Δ) of lipid profile parameters in the period preceding (from 1 month up to 1 year) hospital admission due to COVID-19. Clinical data of 324 patients (mean age 76 ± 15 years, 54% males) hospitalized due to COVID-19 between March 2020 and March 2022 were retrospectively analyzed. The association between TSH levels at hospital admission and either Δ-TC, Δ-LDL-C, or Δ-HDL-C over the selected time frame was assessed through univariable and multivariable analyses. TSH levels were below the lower reference limit of 0.340 μUI/mL in 14% of COVID-19 patients. A significant reduction of plasma TC, LDL-C, and HDL-C was recorded between the two time points (p < 0.001 for all the comparisons). TSH was directly associated with Δ-TC (rho = 0.193, p = 0.001), Δ-LDL-C (rho = 0.201, p = 0.001), and Δ-HDL-C (rho = 0.160, p = 0.008), and inversely associated with C-reactive protein (CRP) (rho = −0.175, p = 0.004). Moreover, TSH decreased with increasing COVID-19 severity (p < 0.001). CRP and COVID-19 severity were inversely associated with Δ-TC, Δ-LDL-C, and Δ-HDL-C (p < 0.05 for all associations). A significant independent association was found between TSH and either Δ-TC (β = 0.125, p = 0.044) or Δ-LDL-C (β = 0.131, p = 0.036) after adjusting for multiple confounders including CRP and COVID-19 severity. In conclusion, lower levels of TSH may contribute to explain TC and LDL-C reduction in the acute phase of COVID-19.

Indexed as

cholesterolCOVID-19LDLSARS-CoV-2thyroidTSH

Identifiers

PMID35743420
PMCPMC9225372
OpenAlexW4281613092

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.